Amgen-Horizon Therapeutics second request by US FTC could address pipeline drugs
1 min read
In MLex, White & Case partner Anna Kertesz is quoted about the Federal Trade Commission's (FTC) pharmaceutical merger review process and what the FTC considers when investigating pharmaceutical pipeline product overlaps.
Drug makers Amgen Inc.'s and Horizon Therapeutics's proposed transaction is being reviewed closely by the FTC. According to the article, the parties are developing treatments for systemic lupus erythematosus and atopic dermatitis, and their pipeline overlaps are a likely area of the FTC's investigation.
In its investigation, the FTC may consider whether the drugs are interchangeable for treating particular conditions, R&D overlaps and other factors. Kertesz notes, "Other significant considerations include whether the technologies would qualify as meaningful scientific advances and how crowded the market is."
See the full MLex article here.
For more information please speak to your local media contact.